Our studies clearly show that tracer Me4FDG is accumulated in pancreatic and prostate tumors in vitro and high-grade glioblastomas in vivo, and this is correlated with the immunochemical detection of SGLT2. Here, SLC5A2 is linked to prostate neoplasm.